Published in J Invest Dermatol on May 01, 2008
Efficacy of Fermented Rice Flour for the Treatment of Atopic Dermatitis | NCT03157284
Mast cells in atopic dermatitis. Curr Opin Immunol (2009) 1.63
Levels of filaggrin degradation products are influenced by both filaggrin genotype and atopic dermatitis severity. Allergy (2011) 1.59
Staphylococcus δ-toxin induces allergic skin disease by activating mast cells. Nature (2013) 1.56
Filaggrin deficiency confers a paracellular barrier abnormality that reduces inflammatory thresholds to irritants and haptens. J Allergy Clin Immunol (2009) 1.52
Nonlesional atopic dermatitis skin is characterized by broad terminal differentiation defects and variable immune abnormalities. J Allergy Clin Immunol (2011) 1.50
Fibroblast growth factor receptors 1 and 2 in keratinocytes control the epidermal barrier and cutaneous homeostasis. J Cell Biol (2010) 1.14
Increase in short-chain ceramides correlates with an altered lipid organization and decreased barrier function in atopic eczema patients. J Lipid Res (2012) 1.11
Global expression profiling in atopic eczema reveals reciprocal expression of inflammatory and lipid genes. PLoS One (2008) 1.06
IL-33: a novel danger signal system in atopic dermatitis. J Invest Dermatol (2012) 1.05
SASPase regulates stratum corneum hydration through profilaggrin-to-filaggrin processing. EMBO Mol Med (2011) 1.02
Peanut allergy: effect of environmental peanut exposure in children with filaggrin loss-of-function mutations. J Allergy Clin Immunol (2014) 1.02
Therapeutic Implications of a Barrier-based Pathogenesis of Atopic Dermatitis. Ann Dermatol (2010) 1.00
Changes of antimicrobial peptides and transepidermal water loss after topical application of tacrolimus and ceramide-dominant emollient in patients with atopic dermatitis. J Korean Med Sci (2010) 0.98
Murine atopic dermatitis responds to peroxisome proliferator-activated receptors alpha and beta/delta (but not gamma) and liver X receptor activators. J Allergy Clin Immunol (2009) 0.97
Atopic dermatitis increases the effect of exposure to peanut antigen in dust on peanut sensitization and likely peanut allergy. J Allergy Clin Immunol (2014) 0.96
Amorphous silica nanoparticles size-dependently aggravate atopic dermatitis-like skin lesions following an intradermal injection. Part Fibre Toxicol (2012) 0.96
Therapeutic implications of a barrier-based pathogenesis of atopic dermatitis. Clin Rev Allergy Immunol (2011) 0.91
Topical antihistamines display potent anti-inflammatory activity linked in part to enhanced permeability barrier function. J Invest Dermatol (2012) 0.90
Expression of epidermal CAMP changes in parallel with permeability barrier status. J Invest Dermatol (2011) 0.90
Immune Pathways in Atopic Dermatitis, and Definition of Biomarkers through Broad and Targeted Therapeutics. J Clin Med (2015) 0.88
Psychoneuroimmunology of psychological stress and atopic dermatitis: pathophysiologic and therapeutic updates. Acta Derm Venereol (2012) 0.86
Application of genetic/genomic approaches to allergic disorders. J Allergy Clin Immunol (2010) 0.86
Paradoxical benefits of psychological stress in inflammatory dermatoses models are glucocorticoid mediated. J Invest Dermatol (2014) 0.86
Induction of oxazolone-mediated features of atopic dermatitis in NOD-scid IL2Rγ(null) mice engrafted with human peripheral blood mononuclear cells. Dis Model Mech (2012) 0.85
Mechanisms of abnormal lamellar body secretion and the dysfunctional skin barrier in patients with atopic dermatitis. J Allergy Clin Immunol (2014) 0.85
Filaggrin genotype determines functional and molecular alterations in skin of patients with atopic dermatitis and ichthyosis vulgaris. PLoS One (2011) 0.85
Lipid abnormalities and lipid-based repair strategies in atopic dermatitis. Biochim Biophys Acta (2013) 0.82
Knockdown of filaggrin in a three-dimensional reconstructed human epidermis impairs keratinocyte differentiation. J Invest Dermatol (2014) 0.82
Vitamin d, the cutaneous barrier, antimicrobial peptides and allergies: is there a link? Allergy Asthma Immunol Res (2013) 0.80
Barrier repair trumps immunology in the pathogenesis and therapy of atopic dermatitis. Drug Discov Today Dis Mech (2008) 0.79
Altered sphingoid base profiles predict compromised membrane structure and permeability in atopic dermatitis. J Dermatol Sci (2013) 0.79
Animal models of skin disease for drug discovery. Expert Opin Drug Discov (2013) 0.79
Epidermal barrier dysfunction in non-atopic HIV: evidence for an "inside-to-outside" pathogenesis. J Invest Dermatol (2009) 0.78
The effect of Psoroptes ovis infestation on ovine epidermal barrier function. Vet Res (2013) 0.78
Impact on inflammation and recovery of skin barrier by nordihydroguaiaretic Acid as a protease-activated receptor 2 antagonist. Biomol Ther (Seoul) (2012) 0.78
Epidermal permeability barrier measurement in mammalian skin. Methods Mol Biol (2011) 0.78
Risk factor-dependent dynamics of atopic dermatitis: modelling multi-scale regulation of epithelium homeostasis. Interface Focus (2013) 0.78
Stratum Corneum Tape Stripping: Monitoring of Inflammatory Mediators in Atopic Dermatitis Patients Using Topical Therapy. Int Arch Allergy Immunol (2016) 0.77
Histologic morphology and involucrin, filaggrin, and keratin expression in normal canine skin from dogs of different breeds and coat types. J Vet Sci (2012) 0.76
Is Montelukast Benefical in Children With Atopic Dermatitis? Allergy Asthma Immunol Res (2016) 0.75
An Appropriate Response to the Black-Box Warning: Corrective, Barrier Repair Therapy in Atopic Dermatitis. Clin Med Dermatol (2009) 0.75
Tight junction proteins in the canine epidermis: a pilot study on their distribution in normal and in high IgE-producing canines. Can J Vet Res (2015) 0.75
Epidermal Dysfunction Leads to an Age-Associated Increase in Levels of Serum Inflammatory Cytokines. J Invest Dermatol (2017) 0.75
Molecular Genetic of Atopic dermatitis: An Update. Int J Health Sci (Qassim) (2016) 0.75
An open-label forearm-controlled pilot study to assess the effect of a proprietary emollient formulation on objective parameters of skin function of eczema-prone individuals over 14 days. Clin Cosmet Investig Dermatol (2017) 0.75
Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis. Nat Genet (2006) 9.99
New insights into atopic dermatitis. J Clin Invest (2004) 5.09
Loss-of-function mutations in the gene encoding filaggrin cause ichthyosis vulgaris. Nat Genet (2006) 4.55
Comprehensive analysis of the gene encoding filaggrin uncovers prevalent and rare mutations in ichthyosis vulgaris and atopic eczema. Nat Genet (2007) 3.94
Agonists of proteinase-activated receptor 2 induce inflammation by a neurogenic mechanism. Nat Med (2000) 3.71
Stratum corneum defensive functions: an integrated view. J Invest Dermatol (2005) 3.20
Cytokine modulation of atopic dermatitis filaggrin skin expression. J Allergy Clin Immunol (2007) 2.79
Atopic dermatitis: new insights and opportunities for therapeutic intervention. J Allergy Clin Immunol (2000) 2.46
Proteinase-activated receptors: transducers of proteinase-mediated signaling in inflammation and immune response. Endocr Rev (2005) 2.42
Neuronal control of skin function: the skin as a neuroimmunoendocrine organ. Physiol Rev (2006) 2.30
Structural and lipid biochemical correlates of the epidermal permeability barrier. Adv Lipid Res (1991) 2.22
Loss-of-function variations within the filaggrin gene predispose for atopic dermatitis with allergic sensitizations. J Allergy Clin Immunol (2006) 2.22
Breaking the (un)sound barrier: filaggrin is a major gene for atopic dermatitis. J Invest Dermatol (2006) 2.17
Basis for the barrier abnormality in atopic dermatitis: outside-inside-outside pathogenic mechanisms. J Allergy Clin Immunol (2008) 2.11
New perspectives on epidermal barrier dysfunction in atopic dermatitis: gene-environment interactions. J Allergy Clin Immunol (2006) 2.06
Ceramide-dominant barrier repair lipids alleviate childhood atopic dermatitis: changes in barrier function provide a sensitive indicator of disease activity. J Am Acad Dermatol (2002) 1.94
Frontiers in pruritus research: scratching the brain for more effective itch therapy. J Clin Invest (2006) 1.90
The skin barrier as an innate immune element. Semin Immunopathol (2007) 1.81
Psychological stress downregulates epidermal antimicrobial peptide expression and increases severity of cutaneous infections in mice. J Clin Invest (2007) 1.72
A proteolytic cascade of kallikreins in the stratum corneum. J Invest Dermatol (2005) 1.58
Neurophysiological, neuroimmunological, and neuroendocrine basis of pruritus. J Invest Dermatol (2006) 1.53
Serine protease signaling of epidermal permeability barrier homeostasis. J Invest Dermatol (2006) 1.51
Skin barrier function and allergic risk. Nat Genet (2006) 1.50
10. Atopic dermatitis. J Allergy Clin Immunol (2006) 1.48
Stress-induced changes in skin barrier function in healthy women. J Invest Dermatol (2001) 1.48
Skin barrier function, epidermal proliferation and differentiation in eczema. J Dermatol Sci (2006) 1.47
The role of microorganisms in atopic dermatitis. Clin Exp Immunol (2006) 1.31
Interactions among stratum corneum defensive functions. Exp Dermatol (2005) 1.28
Activation of proteinase-activated receptor-2 by human kallikrein-related peptidases. J Invest Dermatol (2007) 1.25
Acute modulations in permeability barrier function regulate epidermal cornification: role of caspase-14 and the protease-activated receptor type 2. Am J Pathol (2007) 1.20
Does the tail wag the dog? Role of the barrier in the pathogenesis of inflammatory dermatoses and therapeutic implications. Arch Dermatol (2001) 1.19
Evidence for the existence of a self-regulated enzymatic process within the human stratum corneum -an unexpected role for urocanic acid. J Invest Dermatol (2000) 1.19
Comparison of parent knowledge, therapy utilization and severity of atopic eczema before and after explanation and demonstration of topical therapies by a specialist dermatology nurse. Br J Dermatol (2003) 1.17
Interleukin-4 suppresses the enhancement of ceramide synthesis and cutaneous permeability barrier functions induced by tumor necrosis factor-alpha and interferon-gamma in human epidermis. J Invest Dermatol (2005) 1.15
IL-4 suppresses the recovery of cutaneous permeability barrier functions in vivo. J Invest Dermatol (2007) 1.01
IL-1 beta activation in human epidermis. J Immunol (1996) 1.01
Reciprocal regulation of permeability through a cultured keratinocyte sheet by IFN-gamma and IL-4. Cytokine (2004) 0.90
The neurobiology of itch. Nat Rev Neurosci (2006) 3.25
IL-31: a new link between T cells and pruritus in atopic skin inflammation. J Allergy Clin Immunol (2006) 2.39
Neuronal control of skin function: the skin as a neuroimmunoendocrine organ. Physiol Rev (2006) 2.30
Role for protease activity in visceral pain in irritable bowel syndrome. J Clin Invest (2007) 2.09
Cytokines and chemokines orchestrate atopic skin inflammation. J Allergy Clin Immunol (2006) 2.08
Frontiers in pruritus research: scratching the brain for more effective itch therapy. J Clin Invest (2006) 1.90
The distinct roles of two GPCRs, MrgprC11 and PAR2, in itch and hyperalgesia. Sci Signal (2011) 1.75
Evaluation of protease-activated receptor 2 in murine models of arthritis. Arthritis Rheum (2007) 1.70
Tumor immune escape by the loss of homeostatic chemokine expression. Proc Natl Acad Sci U S A (2007) 1.58
Expression of vanilloid receptor subtype 1 in cutaneous sensory nerve fibers, mast cells, and epithelial cells of appendage structures. Exp Dermatol (2004) 1.52
Protein phosphatase 2A mediates resensitization of the neurokinin 1 receptor. Am J Physiol Cell Physiol (2011) 1.51
Tumor-derived matrix metalloproteinase-1 targets endothelial proteinase-activated receptor 1 promoting endothelial cell activation. Cancer Res (2006) 1.42
Endosomal endothelin-converting enzyme-1: a regulator of beta-arrestin-dependent ERK signaling. J Biol Chem (2009) 1.27
The TGR5 receptor mediates bile acid-induced itch and analgesia. J Clin Invest (2013) 1.27
UVB radiation generates sunburn pain and affects skin by activating epidermal TRPV4 ion channels and triggering endothelin-1 signaling. Proc Natl Acad Sci U S A (2013) 1.26
Activation of proteinase-activated receptor-2 by human kallikrein-related peptidases. J Invest Dermatol (2007) 1.25
Proinflammatory role of proteinase-activated receptor-2 in humans and mice during cutaneous inflammation in vivo. FASEB J (2003) 1.22
Pathophysiology of pruritus in atopic dermatitis: an overview. Exp Dermatol (2002) 1.21
Endothelin-converting enzyme 1 degrades neuropeptides in endosomes to control receptor recycling. Proc Natl Acad Sci U S A (2007) 1.21
Post-endocytic sorting of calcitonin receptor-like receptor and receptor activity-modifying protein 1. J Biol Chem (2007) 1.21
Endothelin-converting enzyme-1 regulates endosomal sorting of calcitonin receptor-like receptor and beta-arrestins. J Cell Biol (2007) 1.20
Colitis induced by proteinase-activated receptor-2 agonists is mediated by a neurogenic mechanism. Can J Physiol Pharmacol (2003) 1.17
Agonists of proteinase-activated receptor-2 stimulate upregulation of intercellular cell adhesion molecule-1 in primary human keratinocytes via activation of NF-kappa B. J Invest Dermatol (2005) 1.16
Retracted A role for proteinase-activated receptor-1 in inflammatory bowel diseases. J Clin Invest (2004) 1.15
Efficacy and safety of once-daily topical brimonidine tartrate gel 0.5% for the treatment of moderate to severe facial erythema of rosacea: results of two randomized, double-blind, and vehicle-controlled pivotal studies. J Drugs Dermatol (2013) 1.14
Agonists of proteinase-activated receptor 2 induce cytokine release and activation of nuclear transcription factor kappaB in human dermal microvascular endothelial cells. J Invest Dermatol (2002) 1.12
Neurophysiology of pruritus: cutaneous elicitation of itch. Arch Dermatol (2003) 1.12
Ubiquitin-dependent down-regulation of the neurokinin-1 receptor. J Biol Chem (2006) 1.12
Neurovascular and neuroimmune aspects in the pathophysiology of rosacea. J Investig Dermatol Symp Proc (2011) 1.10
Characterization of thrombin-induced leukocyte rolling and adherence: a potential proinflammatory role for proteinase-activated receptor-4. J Immunol (2002) 1.10
Neuronal sensitization for histamine-induced itch in lesional skin of patients with atopic dermatitis. Arch Dermatol (2003) 1.09
PAR2 absence completely rescues inflammation and ichthyosis caused by altered CAP1/Prss8 expression in mouse skin. Nat Commun (2011) 1.09
Proteinase-activated receptor-2 in the skin: receptor expression, activation and function during health and disease. Drug News Perspect (2008) 1.08
Recycling and resensitization of the neurokinin 1 receptor. Influence of agonist concentration and Rab GTPases. J Biol Chem (2004) 1.07
Protease-activated receptor-2 activation: a major role in the pathogenesis of Porphyromonas gingivalis infection. Am J Pathol (2006) 1.07
Proteinase-activated receptors: novel signals for peripheral nerves. Trends Neurosci (2003) 1.06
IL-33: a novel danger signal system in atopic dermatitis. J Invest Dermatol (2012) 1.05
Successful treatment of generalized eruptive histiocytoma with PUVA. J Dtsch Dermatol Ges (2007) 1.05
Mouse model of touch-evoked itch (alloknesis). J Invest Dermatol (2012) 1.04
Neurophysiology of pruritus: interaction of itch and pain. Arch Dermatol (2003) 1.03
Distribution and expression of non-neuronal transient receptor potential (TRPV) ion channels in rosacea. J Invest Dermatol (2011) 1.02
Endothelin-converting enzyme-1 degrades internalized somatostatin-14. Endocrinology (2008) 1.01
Pruritus in elderly patients--eruptions of senescence. Semin Cutan Med Surg (2011) 0.98
Par2 inactivation inhibits early production of TSLP, but not cutaneous inflammation, in Netherton syndrome adult mouse model. J Invest Dermatol (2010) 0.98
Neuroimmune interactions in allergic skin diseases. Curr Opin Allergy Clin Immunol (2007) 0.97
Efficacy and safety of ivermectin 1% cream in treatment of papulopustular rosacea: results of two randomized, double-blind, vehicle-controlled pivotal studies. J Drugs Dermatol (2014) 0.96
Agonists of proteinase-activated receptor-2 affect transendothelial migration and apoptosis of human neutrophils. Exp Dermatol (2007) 0.95
Functional characterization and expression analysis of the proteinase-activated receptor-2 in human cutaneous mast cells. J Invest Dermatol (2006) 0.94
Microfluidic reveals generation of platelet-strings on tumor-activated endothelium. Thromb Haemost (2007) 0.92
Role of matriptase and proteinase-activated receptor-2 in nonmelanoma skin cancer. J Invest Dermatol (2009) 0.90
Role of protease-activated receptors in human skin fibrosis and scleroderma. Exp Dermatol (2011) 0.90
Anatomy and neurophysiology of pruritus. Semin Cutan Med Surg (2011) 0.89
Proteinase-activated receptor-1 is an anti-inflammatory signal for colitis mediated by a type 2 immune response. Inflamm Bowel Dis (2005) 0.89
Agonists of proteinase-activated receptor-2 enhance IFN-gamma-inducible effects on human monocytes: role in influenza A infection. J Immunol (2008) 0.89
Management of itch in atopic dermatitis. Semin Cutan Med Surg (2011) 0.89
Endothelin-converting enzyme-1 regulates trafficking and signalling of the neurokinin 1 receptor in endosomes of myenteric neurones. J Physiol (2011) 0.88
Intermedin: a skin peptide that is downregulated in atopic dermatitis. J Invest Dermatol (2006) 0.88
Proteinase-activated receptor-2 (PAR2): a tumor suppressor in skin carcinogenesis. J Invest Dermatol (2007) 0.88
Rosacea: The cytokine and chemokine network. J Investig Dermatol Symp Proc (2011) 0.87
Transient receptor potential ankyrin 1 mediates chronic pancreatitis pain in mice. Am J Physiol Gastrointest Liver Physiol (2013) 0.87
Improvement in facial erythema within 30 minutes of initial application of brimonidine tartrate in patients with rosacea. J Drugs Dermatol (2014) 0.87
Role of spinal neurotransmitter receptors in itch: new insights into therapies and drug development. CNS Neurosci Ther (2010) 0.86
Pruritus and renal failure. Semin Cutan Med Surg (2011) 0.86
Psychoneuroimmunology of psychological stress and atopic dermatitis: pathophysiologic and therapeutic updates. Acta Derm Venereol (2012) 0.86
Long-term safety of ivermectin 1% cream vs azelaic acid 15% gel in treating inflammatory lesions of rosacea: results of two 40-week controlled, investigator-blinded trials. J Drugs Dermatol (2014) 0.86
PAR-2 inhibition reverses experimental pulmonary hypertension. Circ Res (2012) 0.85
Innovative management of pruritus. Dermatol Clin (2010) 0.85
Neural peptidase endothelin-converting enzyme 1 regulates endothelin 1-induced pruritus. J Clin Invest (2014) 0.84
Thrombin receptor: An endogenous inhibitor of inflammatory pain, activating opioid pathways. Pain (2009) 0.84
Serine protease inhibition reduces post-ischemic granulocyte recruitment in mouse intestine. Am J Pathol (2011) 0.84
Localization of mu-opioid receptor 1A on sensory nerve fibers in human skin. Regul Pept (2002) 0.84
Calcineurin inhibitors for the treatment of atopic dermatitis. Expert Opin Pharmacother (2008) 0.83
Histamine and antihistamines in atopic dermatitis. Adv Exp Med Biol (2010) 0.83
Agonist-induced endocytosis of rat somatostatin receptor 1. Endocrinology (2006) 0.83
Neurogenic components of trypsin- and thrombin-induced inflammation in rat skin, in vivo. Exp Dermatol (2006) 0.83
Contribution of bone marrow-derived cells to the pro-inflammatory effects of protease-activated receptor-2 in colitis. Inflamm Res (2010) 0.82
Serum kallikrein-8 correlates with skin activity, but not psoriatic arthritis, in patients with psoriatic disease. Clin Chem Lab Med (2013) 0.82
Rosacea and small intestinal bacterial overgrowth: prevalence and response to rifaximin. J Am Acad Dermatol (2013) 0.82
Preliminary evidence for a role of mast cells in epidermal growth factor receptor inhibitor-induced pruritus. J Am Acad Dermatol (2010) 0.81
Neurogenic rosacea: a distinct clinical subtype requiring a modified approach to treatment. Arch Dermatol (2011) 0.81
New tools for assessing the individual risk of metastasis in renal cell carcinoma. Clin Exp Metastasis (2012) 0.81
Role of proteinase-activated receptor-2 in anti-bacterial and immunomodulatory effects of interferon-γ on human neutrophils and monocytes. Immunology (2011) 0.81
Pituitary adenylate cyclase activating polypeptide: an important vascular regulator in human skin in vivo. Am J Pathol (2010) 0.81
Livedoid vasculopathy in a pediatric patient with elevated lipoprotein(a) levels: prompt response to continuous low-molecular-weight heparin. Arch Dermatol (2010) 0.81
A role for proteinase-activated receptor-1 in inflammatory bowel diseases. J Clin Invest (2006) 0.80
Pathway management in ambulatory wound care: defining local standards for quality improvement and interprofessional care. Int Wound J (2005) 0.79
Proteinase-activated receptors 1 and 2 regulate invasive behavior of human melanoma cells via activation of protein kinase D1. J Invest Dermatol (2011) 0.79
Role of cytokines and chemokines in itch. Handb Exp Pharmacol (2015) 0.79
Recapitulating atopic dermatitis in three dimensions: cross talk between keratinocytes and nerve fibers. J Invest Dermatol (2013) 0.79
α-1-Antitrypsin and IFN-γ reduce the severity of IC-mediated vasculitis by regulation of leukocyte recruitment in vivo. J Invest Dermatol (2012) 0.78
Anti-inflammatory effects of nitric oxide-releasing hydrocortisone NCX 1022, in a murine model of contact dermatitis. Br J Pharmacol (2004) 0.78
Cutaneous allergic contact dermatitis responses are diminished in mice deficient in neurokinin 1 receptors and augmented by neurokinin 2 receptor blockage. FASEB J (2004) 0.78
Intracellular degradation of somatostatin-14 following somatostatin-receptor3-mediated endocytosis in rat insulinoma cells. FEBS J (2008) 0.77
Pruritus/itch: the science and treatment. Introduction. Semin Cutan Med Surg (2011) 0.76
Erythema leprosum--after treatment of Lepromatous Leprosy. J Dtsch Dermatol Ges (2009) 0.76
Interferon-γ induces upregulation and activation of the interleukin-31 receptor in human dermal microvascular endothelial cells. Exp Dermatol (2010) 0.76
Disseminated erosive pustular dermatosis also involving the mucosa: successful treatment with oral dapsone. Acta Derm Venereol (2012) 0.75
Proteinase-activated receptor-2 agonist activates anti-influenza mechanisms and modulates IFNγ-induced antiviral pathways in human neutrophils. Biomed Res Int (2013) 0.75
[Atopic dermatitis. Pathophysiologic background, scientific status quo and therapeutic strategies]. Med Monatsschr Pharm (2005) 0.75
[Persistent plaque on the back and right upper arm. Latent syphilis (lues III) with tubero-ulcero-serpiginous plaque]. J Dtsch Dermatol Ges (2006) 0.75